ReciBioPharm has partnered with pre-clinical gene therapy company GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors.
Austian start-up Sarcura has secured a €1.7 million grant to help the company develop a ‘miniaturized and autonomous’ cell therapy manufacturing platform using deep tech.
Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.
Neurogene, a clinical-stage company developing genetic medicines, is expanding its ongoing phase 1/2 clinical trial investigating NGN-401 as a treatment for female pediatric patients with Rett Syndrome.
OneChain Immunotherapeutics has received €1.9m from the Spanish Ministry of Science and Innovation to advance a ‘groundbreaking’ CAR-T therapy for acute lymphoblastic leukemia type T into clinical development.
The Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Janssen’s CARVYKTI (cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM).
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the treatment of sickle cell disease with vaso-occlusive crisis.
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment...
Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.
We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical...
TrakCel, a provider of cellular orchestration systems to the cell and gene therapy (CGT) industry, has launched its own consultancy services to share its process development knowledge with the broader community of CGT developers.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.
A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers, shakers and key announcements in the pharma industry. From Stand Up To Cancer, Astraveus and KBI Biopharma, we break down the key changes.
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
Johnson & Johnson’s Janssen Supply Group is to be the first tenant in Fujifilm Diosynth Biotechnologies’ $2 billion cell culture manufacturing facility, which is planned to open in Holly Springs, North Carolina, in 2025.
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
The antibody drug nipocalimab, developed by the Janssen Pharmaceutical...
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.
Sarepta Therapeutics has hit a setback as its approved gene therapy Elevidys missed the primary goal of a phase 3 trial in children aged 4 through 7 years with the inherited disease Duchenne muscular dystrophy (DMD).
The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.
Triumvira Immunologics, a Texas-based clinical-stage company developing T cell therapeutics to treat patients with solid tumors, has announced that the first patient has been dosed in its phase 2 trial to treat gastric cancer.
Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), has completed construction of several CGMP manufacturing suites within its new and gene therapy (CGT) development and CGMP manufacturing facility.
SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has partnered with Spark Therapeutics to develop a gene therapy for an inherited retinal disease.
Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms...
Children’s Mercy Kansas City, an independent pediatric health organization, has become the first health care system to replace old genetic tests, such as rapid exome and chromosomal microarray analysis, with the world’s most-advanced genomic sequencing...
OrganaBio, a contract technology development and manufacturing organization (CTDMO) specializing in solutions for cell and immunotherapy development, has launched a new division.
ScaleReady, a cell therapy manufacturing company, and CTMC, a joint venture between National Resilience and the MD Anderson Cancer Center, have entered into a new collaborative partnership
Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, has announced a two-year extension to its contract for the Hong Kong Genome Project (HKGP), the first large-scale genome...